ENPP2 and lung carcinoma: ATX inhibitors have been tested in a variety of cancers, including breast cancer (Tang et al. 2020), lung cancer (Bhave et al. 2013), colorectal cancer (Yun 2019), and melanoma (Jankowski 2011).